466 related articles for article (PubMed ID: 12654245)
1. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation.
Leng RP; Lin Y; Ma W; Wu H; Lemmers B; Chung S; Parant JM; Lozano G; Hakem R; Benchimol S
Cell; 2003 Mar; 112(6):779-91. PubMed ID: 12654245
[TBL] [Abstract][Full Text] [Related]
2. Differential response between the p53 ubiquitin-protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells.
Duan W; Gao L; Wu X; Zhang Y; Otterson GA; Villalona-Calero MA
Exp Cell Res; 2006 Oct; 312(17):3370-8. PubMed ID: 16934800
[TBL] [Abstract][Full Text] [Related]
3. Identification and characterization of two novel isoforms of Pirh2 ubiquitin ligase that negatively regulate p53 independent of RING finger domains.
Corcoran CA; Montalbano J; Sun H; He Q; Huang Y; Sheikh MS
J Biol Chem; 2009 Aug; 284(33):21955-21970. PubMed ID: 19483087
[TBL] [Abstract][Full Text] [Related]
4. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
5. Association of p19(ARF) with Mdm2 inhibits ubiquitin ligase activity of Mdm2 for tumor suppressor p53.
Honda R; Yasuda H
EMBO J; 1999 Jan; 18(1):22-7. PubMed ID: 9878046
[TBL] [Abstract][Full Text] [Related]
6. Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53.
Wang L; He G; Zhang P; Wang X; Jiang M; Yu L
Mol Biol Rep; 2011 Jan; 38(1):229-36. PubMed ID: 20333547
[TBL] [Abstract][Full Text] [Related]
7. The contribution of the acidic domain of MDM2 to p53 and MDM2 stability.
Argentini M; Barboule N; Wasylyk B
Oncogene; 2001 Mar; 20(11):1267-75. PubMed ID: 11313871
[TBL] [Abstract][Full Text] [Related]
8. Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53.
Fang S; Jensen JP; Ludwig RL; Vousden KH; Weissman AM
J Biol Chem; 2000 Mar; 275(12):8945-51. PubMed ID: 10722742
[TBL] [Abstract][Full Text] [Related]
9. Molecular basis of Pirh2-mediated p53 ubiquitylation.
Sheng Y; Laister RC; Lemak A; Wu B; Tai E; Duan S; Lukin J; Sunnerhagen M; Srisailam S; Karra M; Benchimol S; Arrowsmith CH
Nat Struct Mol Biol; 2008 Dec; 15(12):1334-42. PubMed ID: 19043414
[TBL] [Abstract][Full Text] [Related]
10. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53.
Honda R; Tanaka H; Yasuda H
FEBS Lett; 1997 Dec; 420(1):25-7. PubMed ID: 9450543
[TBL] [Abstract][Full Text] [Related]
11. Activity of MDM2, a ubiquitin ligase, toward p53 or itself is dependent on the RING finger domain of the ligase.
Honda R; Yasuda H
Oncogene; 2000 Mar; 19(11):1473-6. PubMed ID: 10723139
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of Pirh2 by calmodulin-dependent kinase II impairs its ability to ubiquitinate p53.
Duan S; Yao Z; Hou D; Wu Z; Zhu WG; Wu M
EMBO J; 2007 Jul; 26(13):3062-74. PubMed ID: 17568776
[TBL] [Abstract][Full Text] [Related]
13. Pirh2 promotes ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27Kip1.
Hattori T; Isobe T; Abe K; Kikuchi H; Kitagawa K; Oda T; Uchida C; Kitagawa M
Cancer Res; 2007 Nov; 67(22):10789-95. PubMed ID: 18006823
[TBL] [Abstract][Full Text] [Related]
14. Polyubiquitination of p53 by a ubiquitin ligase activity of p300.
Grossman SR; Deato ME; Brignone C; Chan HM; Kung AL; Tagami H; Nakatani Y; Livingston DM
Science; 2003 Apr; 300(5617):342-4. PubMed ID: 12690203
[TBL] [Abstract][Full Text] [Related]
15. Residues 240-250 in the C-terminus of the Pirh2 protein complement the function of the RING domain in self-ubiquitination of the Pirh2 protein.
Abou Zeinab R; Wu H; Sergi C; Leng RP
PLoS One; 2013; 8(12):e82803. PubMed ID: 24367557
[TBL] [Abstract][Full Text] [Related]
16. A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control.
Li L; Liao J; Ruland J; Mak TW; Cohen SN
Proc Natl Acad Sci U S A; 2001 Feb; 98(4):1619-24. PubMed ID: 11172000
[TBL] [Abstract][Full Text] [Related]
17. The ubiquitin ligase COP1 is a critical negative regulator of p53.
Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Mdm2 and MdmX fusion proteins alters p53 mediated transactivation, ubiquitination, and degradation.
Ghosh M; Huang K; Berberich SJ
Biochemistry; 2003 Mar; 42(8):2291-9. PubMed ID: 12600196
[TBL] [Abstract][Full Text] [Related]
19. The p53 paddy wagon: COP1, Pirh2 and MDM2 are found resisting apoptosis and growth arrest.
Corcoran CA; Huang Y; Sheikh MS
Cancer Biol Ther; 2004 Aug; 3(8):721-5. PubMed ID: 15280670
[TBL] [Abstract][Full Text] [Related]
20. SUMO-1 modification of Mdm2 prevents its self-ubiquitination and increases Mdm2 ability to ubiquitinate p53.
Buschmann T; Fuchs SY; Lee CG; Pan ZQ; Ronai Z
Cell; 2000 Jun; 101(7):753-62. PubMed ID: 10892746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
